Chimeric Therapeutics is trading at A$0.01, with a -12.50% move apparently reflecting unexplained selling or low-liquidity trading rather than a confirmed fresh catalyst.
- No Chimeric Therapeutics announcement was listed on the ASX for September 14 or September 15, 2026.
- The latest identified clinical update, announced August 19, 2026, involved a second dose-limiting toxicity and halted CHM-2101 enrollment.
- That update does not clearly explain the September 14 decline.